UPDATE: Bank of America Initiates Coverage on Myriad Genetics
According to a research report published this morning, Bank of America has initiated Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and $28 PT.
Bank of America said in the report, "We reinstate Myriad Genetics (MYGN), a leading molecular diagnostics company, with a Neutral rating and $28 price objective. While we are positive about Myriad's initiatives to bolster near-to-midterm sales, we have some reservations about Myriad's long-term growth as its flagship product, BRACAnalysis, matures."
Myriad Genetics closed yesterday at $25.75.
Latest Ratings for MYGN
|Feb 2017||Ladenburg Thalmann||Upgrades||Sell||Neutral|
|Jan 2017||Deutsche Bank||Initiates Coverage On||Sell|
|Nov 2016||Stephens & Co.||Downgrades||Overweight||Equal-Weight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.